Comparative study of anticancer efficacy of aonitine-containing agent BC1 against ascite and solid forms of Ehrlich's carcinoma.
OBJECTIVE
To study anticancer activity of conitine-containing agent BC1 in vivo.


METHODS
BC1 water solution was administered per os to mice bearing ascite or solid form of Ehrlich's carcinoma. Anticancer effect of BC1 administered per os was evaluated by the indexes of tumor growth inhibition and average life span of experimental animals.


RESULTS
BC1 didn't show anticancer activity in the case of ascite form of Ehrlich's carcinoma. At the same time treatment with BC1 resulted in 77.3% growth inhibition of solid form of Ehrlich's carcinoma (p < 0.05).


CONCLUSIONS
BC1 is active in vivo against tumor with angiogenesis-dependent growth.
Dasyukevich
O I
OI
RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine.
Solyanik
G I
GI
D000157:Aconitine / Q000627:therapeutic use*; D031841:Aconitum / Q000737:chemistry*; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D005260:Female; D051379:Mice; D008517:Phytotherapy; D028321:Plant Preparations
D000972:Antineoplastic Agents, Phytogenic; D028321:Plant Preparations; D000157:Aconitine